Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 13/20 | 1.00 |
| ▸ | GSK3B | P49841 | 5/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13304832 | 0.87 | CDK2 (0.98) | CDK2CCNE1GSK3B | |
| SCHEMBL12952859 | 0.85 | GSK3B (1.00) | CDK2CCNE1GSK3B | |
| SCHEMBL30263731 | 0.85 | GSK3B (1.00) | CDK2CCNE1GSK3B | |
| SCHEMBL12952869 | 0.85 | CDK2 (0.83) | CDK2CCNE1GSK3B | |
| SCHEMBL13116732 | 0.83 | CDK2 (0.80) | CDK2CCNE1GSK3B | |
| SCHEMBL12953636 | 0.82 | CDK2 (0.79) | CDK2CCNE1GSK3B | |
| SCHEMBL12952890 | 0.82 | CDK2 (0.79) | CDK2CCNE1GSK3B | |
| SCHEMBL12952864 | 0.81 | CDK2 (0.73) | CDK2CCNE1GSK3B | |
| SCHEMBL12953912 | 0.79 | GSK3B (0.76) | CDK2CCNE1GSK3B | |
| SCHEMBL12952885 | 0.79 | GSK3B (0.76) | CDK2CCNE1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406853-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | Umbra Therapeutics, Inc. (US) | 2023-12-21 | — | — | US | disclosed |
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406853-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | CDK2, CDK20, CDK2AP1 | CDK2 1/4885CCNE1 41/4885GSK3B 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.